High-dose Radiotherapy for Oligo-progressive NSCLC Receiving EGFR Tyrosine Kinase Inhibitors: Real World Data

Area of Science:

• Oncology
• Radiation Oncology
• Medical Oncology

Background:

• Oligo-progressive, EGFR-mutated non-small cell lung cancer (mut-NSCLC) presents a challenge for long-term disease management.
• Local ablative treatments are being investigated to improve outcomes in this patient population.

Purpose of the Study:

• To evaluate the efficacy of hypo-fractionated, high-dose radiation therapy (HDRT) in combination with prolonged EGFR tyrosine kinase inhibitors (TKI) for oligo-progressive, EGFR-mutant NSCLC.

Main Methods:

• Retrospective analysis of 36 patients with oligo-progressive, EGFR-mutant NSCLC treated with HDRT and TKI therapy.
• Progression-free survival-1 (PFS-1) and progression-free survival-2 (PFS-2) were the primary endpoints.
• HDRT modalities included intensity-modulated RT and stereotactic RT.

Main Results:

• Median PFS-1 was 12.5 months.
• Median PFS-2 was 6.3 months.
• The overall survival was 38.7 months.

Conclusions:

• Hypo-fractionated HDRT plus TKI therapy is associated with a significant prolongation of disease control (overall PFS: 18.8 months).
• The treatment regimen demonstrated manageable side effects.
• Real-world data support the use of local ablative approaches for oligo-progressive EGFR-mutant NSCLC.